Clinical Experience with Trastuzumab (Herceptin)

Charles Vogel, Sandra X. Franco

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Trastuzumab is a humanized monoclonal antibody against the epidermal growth factor family oncogene, Her-2/neu. It has revolutionized therapy for the 15-20% of patients with metastatic breast cancer whose tumors have gene amplification for Her-2/neu. Results of clinical trials with single agent trastuzumab and in combination with paclitaxel, docetaxel, vinorelbine, gemcitabine and platinum salts have been encouraging. Durable remissions in excess of 5 years have occasionally been reported. Subjectively the side effect profile of this novel, targeted therapy, has been mild. Cardiac toxicity, while reported in combination regimens with anthracyclines tend to be easily manageable and not absolute contradictions to continuation of trastuzumab. Outside of clinical trials, however, anthracycline/trastuzumab combinations should be avoided. Preliminary results of trials with various combinations of chemotherapeutic agents have been promising while combinations with hormonal and other biologic therapy are ongoing. Trastuzumab is an exciting new monoclonal antibody with interesting anti-tumor activity in patients with Her-2/neu gene amplified breast cancer. We look forward to ongoing clinical trials combining trastuzumab with a broad array of other chemotherapeutic, hormonal and biological agents.

Original languageEnglish
Pages (from-to)452-462
Number of pages11
JournalBreast Journal
Volume9
Issue number6
DOIs
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Anthracyclines
Clinical Trials
docetaxel
gemcitabine
Breast Neoplasms
erbB-2 Genes
Antibodies, Monoclonal, Humanized
Biological Therapy
Gene Amplification
Biological Factors
Paclitaxel
Platinum
Oncogenes
Epidermal Growth Factor
Trastuzumab
Neoplasms
Salts
Monoclonal Antibodies
Therapeutics
Cardiotoxicity

Keywords

  • Clinical trials
  • Herceptin
  • Targeted therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

Clinical Experience with Trastuzumab (Herceptin). / Vogel, Charles; Franco, Sandra X.

In: Breast Journal, Vol. 9, No. 6, 01.11.2003, p. 452-462.

Research output: Contribution to journalArticle

Vogel, Charles ; Franco, Sandra X. / Clinical Experience with Trastuzumab (Herceptin). In: Breast Journal. 2003 ; Vol. 9, No. 6. pp. 452-462.
@article{5ffa2b54d67d485aa6bbf7e6d0ecd855,
title = "Clinical Experience with Trastuzumab (Herceptin)",
abstract = "Trastuzumab is a humanized monoclonal antibody against the epidermal growth factor family oncogene, Her-2/neu. It has revolutionized therapy for the 15-20{\%} of patients with metastatic breast cancer whose tumors have gene amplification for Her-2/neu. Results of clinical trials with single agent trastuzumab and in combination with paclitaxel, docetaxel, vinorelbine, gemcitabine and platinum salts have been encouraging. Durable remissions in excess of 5 years have occasionally been reported. Subjectively the side effect profile of this novel, targeted therapy, has been mild. Cardiac toxicity, while reported in combination regimens with anthracyclines tend to be easily manageable and not absolute contradictions to continuation of trastuzumab. Outside of clinical trials, however, anthracycline/trastuzumab combinations should be avoided. Preliminary results of trials with various combinations of chemotherapeutic agents have been promising while combinations with hormonal and other biologic therapy are ongoing. Trastuzumab is an exciting new monoclonal antibody with interesting anti-tumor activity in patients with Her-2/neu gene amplified breast cancer. We look forward to ongoing clinical trials combining trastuzumab with a broad array of other chemotherapeutic, hormonal and biological agents.",
keywords = "Clinical trials, Herceptin, Targeted therapy, Trastuzumab",
author = "Charles Vogel and Franco, {Sandra X.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1046/j.1524-4741.2003.09602.x",
language = "English",
volume = "9",
pages = "452--462",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Clinical Experience with Trastuzumab (Herceptin)

AU - Vogel, Charles

AU - Franco, Sandra X.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Trastuzumab is a humanized monoclonal antibody against the epidermal growth factor family oncogene, Her-2/neu. It has revolutionized therapy for the 15-20% of patients with metastatic breast cancer whose tumors have gene amplification for Her-2/neu. Results of clinical trials with single agent trastuzumab and in combination with paclitaxel, docetaxel, vinorelbine, gemcitabine and platinum salts have been encouraging. Durable remissions in excess of 5 years have occasionally been reported. Subjectively the side effect profile of this novel, targeted therapy, has been mild. Cardiac toxicity, while reported in combination regimens with anthracyclines tend to be easily manageable and not absolute contradictions to continuation of trastuzumab. Outside of clinical trials, however, anthracycline/trastuzumab combinations should be avoided. Preliminary results of trials with various combinations of chemotherapeutic agents have been promising while combinations with hormonal and other biologic therapy are ongoing. Trastuzumab is an exciting new monoclonal antibody with interesting anti-tumor activity in patients with Her-2/neu gene amplified breast cancer. We look forward to ongoing clinical trials combining trastuzumab with a broad array of other chemotherapeutic, hormonal and biological agents.

AB - Trastuzumab is a humanized monoclonal antibody against the epidermal growth factor family oncogene, Her-2/neu. It has revolutionized therapy for the 15-20% of patients with metastatic breast cancer whose tumors have gene amplification for Her-2/neu. Results of clinical trials with single agent trastuzumab and in combination with paclitaxel, docetaxel, vinorelbine, gemcitabine and platinum salts have been encouraging. Durable remissions in excess of 5 years have occasionally been reported. Subjectively the side effect profile of this novel, targeted therapy, has been mild. Cardiac toxicity, while reported in combination regimens with anthracyclines tend to be easily manageable and not absolute contradictions to continuation of trastuzumab. Outside of clinical trials, however, anthracycline/trastuzumab combinations should be avoided. Preliminary results of trials with various combinations of chemotherapeutic agents have been promising while combinations with hormonal and other biologic therapy are ongoing. Trastuzumab is an exciting new monoclonal antibody with interesting anti-tumor activity in patients with Her-2/neu gene amplified breast cancer. We look forward to ongoing clinical trials combining trastuzumab with a broad array of other chemotherapeutic, hormonal and biological agents.

KW - Clinical trials

KW - Herceptin

KW - Targeted therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=0242721899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242721899&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4741.2003.09602.x

DO - 10.1046/j.1524-4741.2003.09602.x

M3 - Article

VL - 9

SP - 452

EP - 462

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 6

ER -